Vivos Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Vivos Therapeutics
VVOS Stock  USD 2.29  0.19  7.66%   
Vivos Therapeutics financial statements provide useful quarterly and yearly information to potential Vivos Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vivos Therapeutics financial statements helps investors assess Vivos Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vivos Therapeutics' valuation are summarized below:
Gross Profit
9 M
Profit Margin
(0.86)
Market Capitalization
13.7 M
Enterprise Value Revenue
0.5971
Revenue
14.6 M
There are over one hundred nineteen available fundamental trend indicators for Vivos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should double-check Vivos Therapeutics' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 27 M in 2025. Enterprise Value is likely to drop to about 22.5 M in 2025

Vivos Therapeutics Total Revenue

14.14 Million

Check Vivos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 141.3 K, as well as many indicators such as Price To Sales Ratio of 1.79, Dividend Yield of 0.0 or PTB Ratio of 3.91. Vivos financial statements analysis is a perfect complement when working with Vivos Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Vivos Therapeutics Correlation against competitors.
For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Vivos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18 M15.3 M12.4 M
Slightly volatile
Short and Long Term Debt Total2.1 M1.5 M1.3 M
Slightly volatile
Other Current Liabilities2.4 M2.9 M1.4 M
Slightly volatile
Total Current Liabilities7.2 M5 M4.4 M
Slightly volatile
Other Liabilities774 K737.1 K246.1 K
Slightly volatile
Property Plant And Equipment Net3.1 M4.4 M2.1 M
Slightly volatile
Current Deferred Revenue2.6 M2.5 M1.6 M
Slightly volatile
Accounts Payable1.2 M1.1 M809.3 K
Slightly volatile
Cash8.7 M6.3 M4.6 M
Slightly volatile
Non Current Assets Total7.5 M7.8 M6.5 M
Slightly volatile
Non Currrent Assets Other396.3 K216 K254.9 K
Slightly volatile
Other Assets706.8 K409.4 K288.4 K
Slightly volatile
Long Term Debt379.2 K380.8 K475 K
Slightly volatile
Cash And Short Term Investments8.7 M6.3 M4.6 M
Slightly volatile
Net Receivables671.4 K430 K706.7 K
Pretty Stable
Good Will2.3 M2.6 M3.3 M
Slightly volatile
Common Stock Total Equity1.6 K2.1 K1.4 K
Slightly volatile
Common Stock Shares Outstanding6.9 M6.6 M1.4 M
Slightly volatile
Liabilities And Stockholders Equity18 M15.3 M12.4 M
Slightly volatile
Non Current Liabilities Total1.8 M2.4 M1.4 M
Slightly volatile
Other Current Assets1 M783 K550.1 K
Slightly volatile
Other Stockholder Equity72.2 M112.1 M41.9 M
Slightly volatile
Total Liabilities9 M7.3 M5.8 M
Slightly volatile
Net Invested Capital7.4 M8 M7.2 M
Pretty Stable
Property Plant And Equipment Gross4.4 M7.2 M2.7 M
Slightly volatile
Short and Long Term Debt1.7 M1.5 M808.2 K
Slightly volatile
Total Current Assets10.5 M7.5 M5.9 M
Slightly volatile
Short Term Debt898.4 K477 K628.2 K
Slightly volatile
Intangible Assets403.7 K370 K816.2 K
Slightly volatile
Common Stock1.8 K2.3 K1.5 K
Slightly volatile
Property Plant Equipment1.7 M3.2 M1.7 M
Slightly volatile

Vivos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization535.3 K581 K631.5 K
Pretty Stable
Interest Expense1.4 M1.4 M396.5 K
Slightly volatile
Selling General Administrative21.5 M17.9 M14.5 M
Slightly volatile
Selling And Marketing Expenses3.3 M1.7 M2.1 M
Slightly volatile
Total Revenue14.1 M15 M8.4 M
Slightly volatile
Gross Profit9.6 M9 M5.8 M
Slightly volatile
Other Operating Expenses29.9 M26.2 M19.8 M
Slightly volatile
Cost Of Revenue4.5 M6 M2.6 M
Slightly volatile
Total Operating Expenses25.4 M20.2 M17.2 M
Slightly volatile
Reconciled Depreciation537.6 K581 K632.9 K
Pretty Stable
Research Development106.7 K90 K181 K
Slightly volatile

Vivos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.4 M762 K1.5 M
Pretty Stable
Begin Period Cash Flow1.6 M1.6 M4.5 M
Slightly volatile
Depreciation535.3 K581 K631.5 K
Pretty Stable
Capital Expenditures1 M803 K1.1 M
Pretty Stable
Change To Operating Activities217.4 K180 K253.9 K
Slightly volatile
Issuance Of Capital Stock13.2 M7.8 M9.3 M
Slightly volatile
Total Cash From Financing Activities14.7 M17.9 M9.4 M
Slightly volatile
End Period Cash Flow8.7 M6.3 M4.6 M
Slightly volatile
Change To Netincome3.7 M4.4 M2.6 M
Slightly volatile
Change To Inventory240.4 K151.2 K327.4 K
Slightly volatile
Dividends Paid3 M3.3 M3.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.791.888117.0375
Slightly volatile
Days Sales Outstanding9.9210.441841.3631
Slightly volatile
Average Payables623 K700.9 K764.2 K
Slightly volatile
Stock Based Compensation To Revenue0.05540.05830.2411
Slightly volatile
Capex To Depreciation1.121.161.691
Slightly volatile
EV To Sales1.491.572216.7659
Slightly volatile
Inventory Turnover8.39.3310.1766
Slightly volatile
Days Of Inventory On Hand1.0E-42.0E-42.1999
Very volatile
Payables Turnover2.885.47542.8937
Slightly volatile
Sales General And Administrative To Revenue1.771.18942.0366
Slightly volatile
Average Inventory0.550.5790.7 K
Slightly volatile
Research And Ddevelopement To Revenue0.01090.00830.0118
Slightly volatile
Capex To Revenue0.110.06690.2142
Slightly volatile
Cash Per Share0.90.94635.356
Pretty Stable
Days Payables Outstanding12366.6617137
Slightly volatile
Income Quality0.591.13960.6776
Slightly volatile
Intangibles To Total Assets0.310.21020.4417
Slightly volatile
Current Ratio1.141.50121.1645
Pretty Stable
Receivables Turnover20.0134.955815.3785
Slightly volatile
Capex Per Share1.410.761.9711
Slightly volatile
Average Receivables620.5 K698 K761 K
Slightly volatile
Revenue Per Share2.162.272210.4885
Pretty Stable
Interest Debt Per Share0.220.22861.9801
Very volatile
Debt To Assets0.180.09890.124
Slightly volatile
Operating Cycle9.9210.441843.563
Slightly volatile
Days Of Payables Outstanding12366.6617137
Slightly volatile
Ebt Per Ebit1.130.99691.0262
Very volatile
Long Term Debt To Capitalization0.110.10.0865
Pretty Stable
Total Debt To Capitalization0.150.15970.4728
Pretty Stable
Quick Ratio1.141.50121.1627
Pretty Stable
Net Income Per E B T1.031.090.9922
Pretty Stable
Cash Ratio0.941.25750.8596
Slightly volatile
Days Of Inventory Outstanding1.0E-42.0E-42.1999
Very volatile
Days Of Sales Outstanding9.9210.441841.3631
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.21.231.1793
Slightly volatile
Fixed Asset Turnover3.263.43024.4111
Pretty Stable
Debt Ratio0.180.09890.124
Slightly volatile
Price Sales Ratio1.791.888117.0375
Slightly volatile
Asset Turnover0.740.98340.679
Slightly volatile
Gross Profit Margin0.760.60.7076
Pretty Stable

Vivos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap27 M28.4 M77.7 M
Slightly volatile
Enterprise Value22.5 M23.6 M75.8 M
Slightly volatile

Vivos Fundamental Market Drivers

Cash And Short Term Investments6.3 M

Vivos Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About Vivos Therapeutics Financial Statements

Vivos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Vivos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.6 M
Total Revenue15 M14.1 M
Cost Of Revenue6 M4.5 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 1.19  1.77 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.07  0.11 
Revenue Per Share 2.27  2.16 
Ebit Per Revenue(0.74)(0.78)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY